

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10596364	
Filing Date		
First Named Inventor	Filippo Giancotti	
Art Unit		
Examiner Name		
Attorney Docket Number	MSK.P-082	

<b>U.S.PATENTS</b>						<b>Remove</b>
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5766591		1998-06-16	Brooks et al.	
	2	5981478		1999-11-09	Ruosahti et al.	
	3	6291496		2001-09-18	Dannenberg et al.	
	4	6358970		2002-03-19	Duggan et al.	
	5	6645991		2003-11-11	Jonczyk et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

**Add**

<b>U.S.PATENT APPLICATION PUBLICATIONS</b>						<b>Remove</b>
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030224993		2003-12-04	Land et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

**Add****FOREIGN PATENT DOCUMENTS****Remove**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10596364
Filing Date	
First Named Inventor	Filippo Giancotti
Art Unit	
Examiner Name	
Attorney Docket Number	MSK.P-082

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T5
	1	2005052122	WO			Sloan-Kettering Institute for Cancer Research		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	BACHELDER, R. et al. " Activation of p53 Function in Carcinoma Cells by the $\alpha 6\beta 4$ Integrin." The Journal of Biological Chemistry. 1999, Volume 274, Number 29, page(s) 20733-20737	<input type="checkbox"/>
	2	DAEMI, N. et al. "Anti- $\beta 4$ Integrin Antibodies Enhance Migratory and Invasive Abilities of Human Colon Adenocarcinoma Cells and Their MMP-2 Expression." Int. J. Cancer. 2000, Volume 85, page(s) 850-856	<input type="checkbox"/>
	3	DAJEE, M. et al. "NF-kappaB blockade and oncogenic Ras Trigger invasive human epidermal neoplasia." Nature. February 2003, Vol. 421, page(s) 639-643	<input type="checkbox"/>
	4	FALCIONI, R. et al. " $\alpha 6\beta 4$ and $\alpha 6\beta 1$ Integrins Associate with ErbB-2 in Human Carcinoma Cell Lines." Experimental Cell Research. 1997, Volume 236, Page(s) 76-85	<input type="checkbox"/>
	5	MAINIERO, F. et al. "The coupling of $\alpha 6\beta 4$ integrin to Ras-MAP kinase pathways mediated by Shc controls keratinocyte proliferation." The EMBO Journal. 1997. Volume 16, Number 9, page(s) 2365-2375	<input type="checkbox"/>
	6	MARIOTTI, A. et al. " EGF-R signaling through Fyn kinase disrupts the function of integrin $\alpha 6\beta 4$ at hemidesmosomes: role in epithelial cell migration and carcinoma invasion." The Journal of Cell Biology. 29 October 2001. Volume 155, Number 3, page(s) 447-457	<input type="checkbox"/>
	7	PEEHL, D. et al. "Anchorage-independent growth of normal human fibroblasts." Proc. Natl. Acad. Sci. USA. 1981. Volume 78, Number 5, page(s) 3053-3057	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10596364	
Filing Date		
First Named Inventor	Filippo Giancotti	
Art Unit		
Examiner Name		
Attorney Docket Number	MSK.P-082	

	8	SHAW, L. et al. "Activation of Phosphoinositide 3-OH Kinase by the $\alpha 6\beta 4$ Integrin Promotes Carcinoma Invasion." Cell. 26 December 1997. Volume 91, page(s) 949-960	<input type="checkbox"/>
	9	STANBRIDGE, E. et al. "Analysis of malignancy in human cells: Malignant and transformed phenotypes are under separate genetic control." Proc. Natl. Acad. Sci. 1978. Volume 75, Number 3, page(s) 1466-1469	<input type="checkbox"/>
	10	STANBRIDGE, E. et al. "Dissociation of Anchorage Independence from Tumorigenicity in Human Cell Hybrids." Int. J. Cancer. 1980. Volume 26, page(s) 1-8	<input type="checkbox"/>
	11	TRUSOLINO, L. et al. "A Signaling Adapter Function for $\alpha 6\beta 4$ Integrin in the Control of HGF-Dependent Invasive Growth." Cell. 30 November 2001. Volume 107, page(s) 643-654	<input type="checkbox"/>
	12	VARMUS, H. "The New Era in Cancer Research." Science. 26 May 2006. Volume 312, page(s) 1162-1165	<input type="checkbox"/>
	13	WATARI, A. et al. "Suppression of tumorigenicity, but not anchorage independence, of human cancer cells by new candidate tumor suppressor gene CapG." Oncogene. 2006. Volume 25, page(s) 7373-7380	<input type="checkbox"/>
	14	WEAVER, V. et al. "4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium." Cancer Cell. 1997. Volume 2, page(s) 205-216	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.